{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:35:31Z","timestamp":1778812531747,"version":"3.51.4"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bpobgyn.2025.102673","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:10:46Z","timestamp":1761869446000},"page":"102673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Fetal therapy with mTOR inhibitors in cardiac rhabdomyoma and lymphatic malformations"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1415-2086","authenticated-orcid":false,"given":"Nikan","family":"Zargarzadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pegah","family":"Rashidian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tishi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalda","family":"Afshar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2025.102673_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1340271","article-title":"Prenatal diagnosis and clinical management of cardiac rhabdomyoma: a single-center study","volume":"11","author":"Peng","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00383-016-3867-4","article-title":"Pediatric lymphatic malformations: evolving understanding and therapeutic options","volume":"32","author":"Defnet","year":"2016","journal-title":"Pediatr Surg Int"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1196\/annals.1413.016","article-title":"Congenital lymphatic malformations","volume":"1131","author":"Blei","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-018-0870-y","article-title":"Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study","volume":"13","author":"Ebrahimi-Fakhari","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-2-11","article-title":"Cardiac tumours in children","volume":"2","author":"Uzun","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s00246-003-0590-4","article-title":"Fetal and neonatal cardiac tumors","volume":"25","author":"Isaacs","year":"2004","journal-title":"Pediatr Cardiol"},{"issue":"10","key":"10.1016\/j.bpobgyn.2025.102673_bib7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/pd.2590","article-title":"Fetal cardiac tumors: a single\u2010center experience of 40 cases","volume":"30","author":"Yinon","year":"2010","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib8","series-title":"Seminars in pediatric surgery","article-title":"Lymphatic malformations","year":"2020"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.17688","article-title":"Topical sirolimus therapy for cutaneous vascular anomalies: a randomized phase II clinical trial","author":"Jinnin","year":"2025","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cps.2010.08.006","article-title":"Management of lymphatic malformations","volume":"38","author":"Greene","year":"2011","journal-title":"Clin Plast Surg"},{"issue":"10","key":"10.1016\/j.bpobgyn.2025.102673_bib11","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00431-010-1235-2","article-title":"Clinical practice. Protein-losing enteropathy in children","volume":"169","author":"Braamskamp","year":"2010","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib12","first-page":"48","article-title":"Cardiac rhabdomyoma in intrauterine life: clinical features and natural history. A case series and review of published reports","volume":"3","author":"Pipitone","year":"2002","journal-title":"Ital Heart J"},{"issue":"3","key":"10.1016\/j.bpobgyn.2025.102673_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pedneo.2016.07.004","article-title":"Fetal primary cardiac tumors during perinatal period","volume":"58","author":"Yuan","year":"2017","journal-title":"Pediatric Neonatol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/pd.6492","article-title":"Mammalian target of rapamycin inhibitors: a new\u2010possible approach for in\u2010utero medication therapy","volume":"44","author":"Qaderi","year":"2024","journal-title":"Prenat Diagn"},{"issue":"6","key":"10.1016\/j.bpobgyn.2025.102673_bib15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/biom12060802","article-title":"The translational regulation in mTOR pathway","volume":"12","author":"Yang","year":"2022","journal-title":"Biomolecules"},{"issue":"16","key":"10.1016\/j.bpobgyn.2025.102673_bib16","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.3390\/molecules27165295","article-title":"Overview of research into mTOR inhibitors","volume":"27","author":"Mao","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.bpobgyn.2025.102673_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4174\/astr.2024.106.3.125","article-title":"Successful outcome with oral sirolimus treatment for complicated lymphatic malformations: a retrospective multicenter cohort study","volume":"106","author":"Cho","year":"2024","journal-title":"Annals Surg Treatment Res"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pediatrneurol.2021.09.014","article-title":"Prenatal sirolimus treatment for rhabdomyomas in tuberous sclerosis","volume":"125","author":"Ebrahimi-Fakhari","year":"2021","journal-title":"Pediatr Neurol"},{"issue":"9639","key":"10.1016\/j.bpobgyn.2025.102673_bib19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bpobgyn.2025.102673_bib20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41372-023-01673-w","article-title":"Study on prenatal diagnosis and pregnancy outcome analysis of fetuses with cardiac rhabdomyoma","volume":"43","author":"Zhai","year":"2023","journal-title":"J Perinatol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2025.102673_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/uog.5264","article-title":"Outcome of antenatally diagnosed cardiac rhabdomyoma: case series and a meta\u2010analysis","volume":"31","author":"Chao","year":"2008","journal-title":"Ultrasound Obstet Gynecol: The Offic J Int Soc Ultrasound in Obstetrics and Gynecology"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00246-010-9874-7","article-title":"Fetal demise secondary to massive rhabdomyoma in the early second trimester of pregnancy","volume":"32","author":"Sharma","year":"2011","journal-title":"Pediatr Cardiol"},{"issue":"18","key":"10.1016\/j.bpobgyn.2025.102673_bib23","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1080\/14767058.2020.1822316","article-title":"Outcomes of antenatally diagnosed fetal cardiac tumors: a 10-year experience at a single tertiary referral center","volume":"35","author":"Okmen","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/pediatric15010020","article-title":"Successful prenatal treatment of cardiac rhabdomyoma in a fetus with tuberous sclerosis","volume":"15","author":"Will","year":"2023","journal-title":"Pediatr Rep"},{"issue":"3","key":"10.1016\/j.bpobgyn.2025.102673_bib25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/pd.5613","article-title":"Fetal cardiac rhabdomyomas treated with maternal sirolimus","volume":"40","author":"Pluym","year":"2020","journal-title":"Prenat Diagn"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13023-025-03780-7","article-title":"Transplacental sirolimus: a new treatment strategy for life-threatening fetal cardiac rhabdomyomas-a case report","volume":"20","author":"Uno","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.bpobgyn.2025.102673_bib27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.5468\/ogs.2019.62.4.280","article-title":"Sirolimus therapy for fetal cardiac rhabdomyoma in a pregnant woman with tuberous sclerosis","volume":"62","author":"Park","year":"2019","journal-title":"Obstetric Gynecol Sci"},{"issue":"19","key":"10.1016\/j.bpobgyn.2025.102673_bib28","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMc1800352","article-title":"Maternal sirolimus therapy for fetal cardiac rhabdomyomas","volume":"378","author":"Barnes","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bpobgyn.2025.102673_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/uog.20196","article-title":"In-utero treatment of large symptomatic rhabdomyoma with sirolimus","volume":"53","author":"Vachon\u2010Marceau","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.bpobgyn.2025.102673_bib30","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1007\/s00381-021-05218-4","article-title":"Everolimus as a possible prenatal treatment of in utero diagnosed subependymal lesions in Tuberous sclerosis complex: a case report","volume":"37","author":"Cavalheiro","year":"2021","journal-title":"Childs Nerv Syst"},{"issue":"2","key":"10.1016\/j.bpobgyn.2025.102673_bib31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cns3.20070","article-title":"Preventative treatment of Tuberous sclerosis complex with sirolimus: phase I safety and efficacy results","volume":"2","author":"Capal","year":"2024","journal-title":"Annals Child Neurol Soc"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2022.03.003","article-title":"Sirolimus treatment for Tuberous sclerosis complex prior to epilepsy: evidence from a registry-based real-world study","volume":"97","author":"Shen","year":"2022","journal-title":"Seizure - Eur J Epilepsy"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib33","author":"Stopping"},{"issue":"3","key":"10.1016\/j.bpobgyn.2025.102673_bib34","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/pd.5613","article-title":"Fetal cardiac rhabdomyomas treated with maternal sirolimus","volume":"40","author":"Pluym","year":"2020","journal-title":"Prenat Diagn"},{"issue":"8","key":"10.1016\/j.bpobgyn.2025.102673_bib35","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/jog.13369","article-title":"Everolimus in pregnancy: case report and literature review","volume":"43","author":"Yamamura","year":"2017","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106884","article-title":"Paradigm shift in the treatment of tuberous sclerosis: effectiveness of everolimus","volume":"195","author":"Previtali","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib37","first-page":"1","article-title":"Transplacental sirolimus for reversal of fetal heart failure due to fetal cardiac rhabdomyoma: fetal and maternal considerations","author":"Gon\u00e7alves","year":"2025","journal-title":"Fetal Diagn Ther"},{"issue":"5","key":"10.1016\/j.bpobgyn.2025.102673_bib38","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1080\/15513815.2021.1948646","article-title":"Fetal tuberous sclerosis: sirolimus for the treatment of fetal rhabdomyoma","volume":"41","author":"Dagge","year":"2022","journal-title":"Fetal Pediatr Pathol"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/pd.6640","article-title":"Characteristics and outcomes of fetal cardiac rhabdomyoma with or without mTOR inhibitors, a systematic review and meta\u2010analysis","author":"Mustafa","year":"2024","journal-title":"Prenat Diagn"},{"issue":"9","key":"10.1016\/j.bpobgyn.2025.102673_bib40","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.3390\/ijerph18094907","article-title":"Treatment of cardiac rhabdomyomas with mTOR inhibitors in children with tuberous sclerosis complex\u2014a systematic review","volume":"18","author":"Sugalska","year":"2021","journal-title":"Int J Environ Res Publ Health"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib41","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13023-022-02266-0","article-title":"Perfect match: mTOR inhibitors and Tuberous sclerosis complex","volume":"17","author":"Luo","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/ped.15219","article-title":"Successful treatment with everolimus for severe heart failure with large cardiac rhabdomyomas","volume":"64","author":"Inoue","year":"2022","journal-title":"Pediatr Int"},{"issue":"16","key":"10.1016\/j.bpobgyn.2025.102673_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612886","article-title":"Three-year Follow-Up after intrauterine mTOR inhibitor administration for fetus with TSC-associated rhabdomyoma","volume":"24","author":"Ma\u00e1sz","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.bpobgyn.2025.102673_bib44","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s00246-024-03420-0","article-title":"Cardiac rhabdomyomas presenting with critical cardiac obstruction in neonates and infants: treatment strategies and outcome, A single-center experience","volume":"45","author":"Ng","year":"2024","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib45","article-title":"Updated classification of vascular anomalies: a living document from the international society for the study of vascular anomalies classification group","volume":"6","author":"Goldenberg","year":"2025","journal-title":"J zascular Anomalies"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1161\/CIRCRESAHA.121.318142","article-title":"Lymphatic malformations: genetics, mechanisms and therapeutic strategies","volume":"129","author":"M\u00e4kinen","year":"2021","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.bpobgyn.2025.102673_bib47","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/MOH.0000000000000496","article-title":"PIK3CA mutations in vascular malformations","volume":"26","author":"Castillo","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"10.1016\/j.bpobgyn.2025.102673_bib48","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/s41436-018-0390-0","article-title":"A somatic activating NRAS variant associated with kaposiform lymphangiomatosis","volume":"21","author":"Barclay","year":"2019","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.bpobgyn.2025.102673_bib49","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1172\/JCI71614","article-title":"Genetics of lymphatic anomalies","volume":"124","author":"Brouillard","year":"2014","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.bpobgyn.2025.102673_bib50","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/MOP.0000000000000209","article-title":"Management of lymphatic malformations in children","volume":"27","author":"Bagrodia","year":"2015","journal-title":"Curr Opin Pediatr"},{"issue":"4","key":"10.1016\/j.bpobgyn.2025.102673_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvir.2019.100631","article-title":"Common (cystic) lymphatic malformations: current knowledge and management","volume":"22","author":"Dubois","year":"2019","journal-title":"Tech Vasc Intervent Radiol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2025.102673_bib52","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1053\/j.sempedsurg.2014.07.002","article-title":"Lymphatic malformations: diagnosis and management","volume":"23","author":"Elluru","year":"2014","journal-title":"Semin Pediatr Surg"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jpedsurg.2016.10.025","article-title":"Prenatal growth characteristics of lymphatic malformations","volume":"52","author":"Peranteau","year":"2017","journal-title":"J Pediatr Surg"},{"issue":"4","key":"10.1016\/j.bpobgyn.2025.102673_bib54","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3233\/NPM-230160","article-title":"A case series of fetal lymphatic malformations and a review of the literature","volume":"16","author":"Papaccio","year":"2023","journal-title":"J Neonatal Perinat Med"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib56","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1038\/s41467-020-16496-y","article-title":"Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation","volume":"11","author":"Martinez-Corral","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib57","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/s13063-022-06365-y","article-title":"Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial","volume":"23","author":"Marchand","year":"2022","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.bpobgyn.2025.102673_bib58","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.bpobgyn.2025.102673_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpedsurg.2025.162223","article-title":"Management, trends, and recommendations for intra-abdominal lymphatic malformations: a single-center retrospective review","volume":"60","author":"Vore","year":"2025","journal-title":"J Pediatr Surg"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13023-022-02608-y","article-title":"French national diagnosis and care protocol (PNDS, protocole national de diagnostic et de soins): cystic lymphatic malformations","volume":"18","author":"Leboulanger","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/ped.15497","article-title":"Pediatric case of acquired progressive lymphatic anomaly treated with sirolimus","volume":"65","author":"Komamizu","year":"2023","journal-title":"Pediatr Int"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib62","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jss.2024.08.026","article-title":"Ex utero intrapartum treatment for prenatally diagnosed cervicofacial lymphatic malformations","volume":"303","author":"Gillipelli","year":"2024","journal-title":"J Surg Res"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1304133","article-title":"Clinical effectiveness and safety of sirolimus in pediatric patients with complex vascular anomalies: necessitating personalized and comprehensive approaches","volume":"11","author":"Kim","year":"2023","journal-title":"Frontiers in Pediatric"},{"issue":"8","key":"10.1016\/j.bpobgyn.2025.102673_bib64","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s00405-022-07378-8","article-title":"Efficacy of sirolimus in children with lymphatic malformations of the head and neck","volume":"279","author":"Wiegand","year":"2022","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2025.102673_bib65","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/lrb.2017.0062","article-title":"Treatment of lymphatic malformations with the mTOR inhibitor sirolimus: a systematic review","volume":"16","author":"Wiegand","year":"2018","journal-title":"Lymphatic Res Biol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2025.102673_bib66","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1089\/lrb.2018.0068","article-title":"Oral sirolimus: an option in the management of neonates with life-threatening upper airway lymphatic malformations","volume":"17","author":"Triana","year":"2019","journal-title":"Lymphatic Res Biol"},{"issue":"6","key":"10.1016\/j.bpobgyn.2025.102673_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2024.104422","article-title":"Healthcare utilization in patients with head and neck lymphatic malformations with the introduction of sirolimus","volume":"45","author":"Kitchloo","year":"2024","journal-title":"Am J Otolaryngol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2025.102673_bib68","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/uog.29191","article-title":"Prenatal treatment of axillary cystic lymphatic malformation using rapamycin","volume":"65","author":"M\u00e9gier","year":"2025","journal-title":"Ultrasound Obstet Gynecol : the offic J Int Soc Ultrasound in Obstetrics and Gynecol"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/pd.6834","article-title":"In-Utero therapy for fetal vascular anomalies: efficacy and tolerance of sirolimus administered to the pregnant patient","author":"Iacobas","year":"2025","journal-title":"Prenat Diagn"},{"issue":"6","key":"10.1016\/j.bpobgyn.2025.102673_bib70","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s44161-023-00280-4","article-title":"A case report of sirolimus use in early fetal management of lymphatic malformation","volume":"2","author":"Seront","year":"2023","journal-title":"Nature Cardiovascular Res"},{"issue":"7","key":"10.1016\/j.bpobgyn.2025.102673_bib71","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/pd.5925","article-title":"Fetal therapy using rapamycin for a rapidly enlarging, obstructive, cervical lymphatic malformation: a case report","volume":"41","author":"Livingston","year":"2021","journal-title":"Prenat Diagn"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib72","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/lio2.241","article-title":"Clinical application of molecular genetics in lymphatic malformations","volume":"4","author":"Padia","year":"2019","journal-title":"Laryngoscope Investigative Otolaryngology"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib73","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1186\/s12884-023-06129-9","article-title":"Maternal and obstetric outcomes after Ex-Utero intrapartum treatment (EXIT): a single center experience","volume":"23","author":"Dom\u00ednguez-Moreno","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"issue":"8","key":"10.1016\/j.bpobgyn.2025.102673_bib74","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/pd.5477","article-title":"Obstetric outcomes of ex-utero intrapartum treatment (EXIT)","volume":"39","author":"Shamshirsaz","year":"2019","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.bpobgyn.2025.102673_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/s41390-025-04043-8","article-title":"Everolimus and sirolimus in the treatment of cardiac rhabdomyomas in neonates","author":"Hurtado-Sierra","year":"2025","journal-title":"Pediatr Res"},{"issue":"9","key":"10.1016\/j.bpobgyn.2025.102673_bib76","article-title":"Safety evaluation of oral sirolimus in the treatment of childhood diseases: a systematic review","volume":"9","author":"Zhang","year":"2022","journal-title":"Children (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib77","first-page":"86","article-title":"Sirolimus in the treatment of vascular anomalies","volume":"27","author":"Triana","year":"2017","journal-title":"Eur J Pediatr Surg"},{"issue":"2","key":"10.1016\/j.bpobgyn.2025.102673_bib78","doi-asserted-by":"crossref","first-page":"19","DOI":"10.22551\/2021.31.0802.10180","article-title":"Maternal sirolimus therapy and fetal growth restriction","volume":"8","author":"Tshering","year":"2021","journal-title":"Arch Clin Cases"},{"issue":"Pt 1","key":"10.1016\/j.bpobgyn.2025.102673_bib79","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1113\/jphysiol.2007.129676","article-title":"Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth","volume":"582","author":"Roos","year":"2007","journal-title":"J Physiol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2025.102673_bib80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13023-021-01776-7","article-title":"Pregnancy after the diagnosis of lymphangioleiomyomatosis (LAM)","volume":"16","author":"Shen","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"10.1016\/j.bpobgyn.2025.102673_bib81","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","article-title":"Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of Tuberous sclerosis complex","volume":"17","author":"MacKeigan","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2025.102673_bib82","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","article-title":"Common toxicities of mammalian target of rapamycin inhibitors","volume":"6","author":"Soefje","year":"2011","journal-title":"Targeted Oncol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2025.102673_bib83","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant Rev"},{"issue":"8","key":"10.1016\/j.bpobgyn.2025.102673_bib84","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1586\/1744666X.2013.824243","article-title":"Impact of mTOR-I on fertility and pregnancy: state of the art and review of the literature","volume":"9","author":"Framarino-dei-Malatesta","year":"2013","journal-title":"Expet Rev Clin Immunol"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693425000975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693425000975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T16:42:15Z","timestamp":1764780135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693425000975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":83,"alternative-id":["S1521693425000975"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2025.102673","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fetal therapy with mTOR inhibitors in cardiac rhabdomyoma and lymphatic malformations","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2025.102673","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102673"}}